61O First-in-human phase I evaluation of HCB101, a SIRPα–Fc innate checkpoint fusion protein: Safety, pharmacokinetics, and receptor occupancy

Read full text Summarise with VIRAT
Authors: F. Ning, Nicholas O. Iannotti, W-H. Cheng, J. Ma, C-C. Lin, Y. Wang, P.M-H. Chang, W. Edenfield, W. Li, T. Zhang, J. Zhang, F. Mo
+2 more A. Yu, Alvin Y. Luk
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

HCB101 is a rationally engineered SIRPα-Fc fusion protein designed to improve the safety and activity of CD47 pathway inhibition through reduced red-blood-cell binding, minimized cytopenias, and enhanced macrophage activation. Preclinical studies in >80 xenograft and PDX models demonstrated potent CD47–SIRPα blockade, strong innate immune activation, and a broad therapeutic window. This first-in-human study evaluates the safety, pharmacokinetics (PK), receptor occupancy (RO), and pharmacodynamic (PD) effects of HCB101 in advanced cancers.

Fields of Study & Subjects

Phagocytosis and Immune Regulation Cancer Immunotherapy and Biomarkers Monoclonal and Polyclonal Antibodies Research

Publication details

Journal / source
ESMO Open
Volume
11
Pages
106202–106202
Publication date
1 April 2026
Language
EN